Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Title Grant Type Focus Area Country Application Due Date Enhancing HCPs’ Preparedness: Maternal Immunization Knowledge UpdatesRelease Date:Education Vaccines USA Real-World Clinical Outcomes Among Adult and Adolescent Patients with Severe Alopecia Areata Receiving Ritlecitinib in ChinaRelease Date:Research Inflammation & Immunology China Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic BladderRelease Date:Education Internal Medicine Japan Interventional Research Studies with ElranatamabRelease Date:Research Oncology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Brazil, India, Mexico, Saudi Arabia, Taiwan, Turkey Advances in the Management of Ulcerative Colitis (UC)Release Date:Education Inflammation & Immunology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology USA BCMA-Directed Bispecific Antibody Treatment in Multiple MyelomaRelease Date:Education Oncology Japan Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophiliaRelease Date:Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)Release Date:Education Rare Disease All Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)Education Oncology USA